Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8443558 | European Journal of Cancer | 2014 | 5 Pages |
Abstract
Delaying major treatments in stage IV MM for a few weeks permits a measure of KI, which is the best prognostic indicator in MM. The huge range of KI probably reflects major differences in aggressiveness that any therapeutic decision should take into account. KI could be used to assess prospectively how much the efficacy of each new MM drugs is influenced by MM initial kinetics.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Caroline Gaudy-Marqueste, Elodie Archier, Anaïs Grob, Olivier Durieux, Anderson Loundou, Marie-Aleth Richard, Jean-Jacques Grob,